Sweetch Secures $20 Million Series A to Accelerate Fully Automated Hyper-Personalized Engagement Between Health Ecosystem Players and People with Chronic Conditions

HRS Scientific Sessions: Boston Scientific LBCT

During the Heart Rhythm Scientific Sessions this week, Boston Scientific announced positive LBCT data underscoring the safety and efficacy of multi-site pacing (MSP) over conventional cardiac resynchronization therapy (CRT), as well as poster presentations on real-world use of the WATCHMAN Left Atrial Appendage Closure (LAAC) device and next-generation WATCHMAN FLX LAAC device as alternatives to oral anticoagulation therapy for stroke risk reduction in patients with non-valvular atrial fibrillation.

What are the Most Commonly Performed Surgeries?

Whether you are trying to learn more about a surgery you are planning to have or find out what the most common procedures are, this list is here for you. Read more.

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

Sweetch, a digital therapeutics innovator and creator of the hyper-personalized engagement platform for chronic conditions, today announced the completion of a $20 million Series A round of funding.

The funds will be directed toward the company’s continued global expansion and further development of its artificial intelligence (AI) and emotional intelligence (EI) behavioral science technology that engages individuals to achieve their health goals with the right message in the right tone, time and real-world context.

The Series A was led by Entrée Capital. It was joined by Tal Capital, Netherlands-based impact investor Noaber, Brazil-based Kortex Ventures, and Insurtech VC FinTLV Ventures, as well as existing investors Philips, OurCrowd and Qure Ventures.

90 percent of healthcare costs in the US are attributable to chronic diseases, which afflict 50 percent of the population. We need a scalable solution to provide better care at lower costs. This seemingly contradictory statement can be achieved through technology like Sweetch,” said Dr. Doron Dinstein, Venture Partner at Entrée Capital. “Sweetch’s digital therapeutic platform provides sustainable behavior changes and has been shown to significantly impact people’s lives. We see the company radically improving the economics of healthcare.”

The Sweetch mobile intervention program is being used around the world as an effective method for achieving sustainable engagement and improved clinical outcomes across various dimensions of chronic disease management. In a clinical trial conducted at Johns Hopkins University’s Division of Endocrinology, Diabetes and Metabolism, Sweetch’s fully automated intervention achieved 86 percent retention and significantly improved clinical outcomes for patients with early-stage diabetes, including lowering HbA1c levels, a diabetes biomarker for blood sugar.

Sweetch provides a hyper-personalized, scalable and cost-effective solution to increase patient adherence across various aspects of disease management and improve clinical outcomes for people with chronic conditions. The company’s proprietary JITAI technology converts millions of data points originating from an individual’s smartphone and other connected devices into hyper-personalized recommendations in just the right tone, time and real-world context to catalyze behavioral change as part of their daily routine. JITAI technology can be used across multiple chronic conditions, including cardio-metabolic diseases, autoimmune disorders and oncology.

“We believe that every person with chronic conditions should have a trusted voice empowering them to reach their micro-goals every step of the way throughout their unique health journey,” said Yoni Nevo, CEO of Sweetch. “The rapidly evolving remote health era is missing a critical component: effective continuous relationships between pharmaceutical companies, device manufacturers, payers, healthcare providers and each of their individual patients. Sweetch provides this missing critical capability at scale to outsmart chronic conditions, together.”




Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.